WithdrawnNCT04234516
Anti-suicidal Effects of Buprenorphine in Addiction
Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 20, 2020
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- New York State Psychiatric Institute
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04234516
- Official title
Show the full official title
Functional Brain Mechanisms Underlying the Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder
Recruitment & locations
WithdrawnNew York
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is New York State Psychiatric Institute, a research institute.
Does this study involve medication?
Yes. The study involves medication, including Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film and Morphine Sulfate 30 mg.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
